212 related articles for article (PubMed ID: 21417417)
1. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
Jorda R; Havlícek L; McNae IW; Walkinshaw MD; Voller J; Sturc A; Navrátilová J; Kuzma M; Mistrík M; Bártek J; Strnad M; Krystof V
J Med Chem; 2011 Apr; 54(8):2980-93. PubMed ID: 21417417
[TBL] [Abstract][Full Text] [Related]
2. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
3. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
Jorda R; Paruch K; Krystof V
Curr Pharm Des; 2012; 18(20):2974-80. PubMed ID: 22571665
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.
Popowycz F; Fournet G; Schneider C; Bettayeb K; Ferandin Y; Lamigeon C; Tirado OM; Mateo-Lozano S; Notario V; Colas P; Bernard P; Meijer L; Joseph B
J Med Chem; 2009 Feb; 52(3):655-63. PubMed ID: 19128055
[TBL] [Abstract][Full Text] [Related]
11. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
12. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
13. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
14. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
16. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
Trávnícek Z; Krystof V; Sipl M
J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
[TBL] [Abstract][Full Text] [Related]
17. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
[TBL] [Abstract][Full Text] [Related]
18. 3,5,7-Substituted Pyrazolo[4,3-
Jorda R; Havlíček L; Peřina M; Vojáčková V; Pospíšil T; Djukic S; Škerlová J; Grúz J; Renešová N; Klener P; Řezáčová P; Strnad M; Kryštof V
J Med Chem; 2022 Jul; 65(13):8881-8896. PubMed ID: 35749742
[TBL] [Abstract][Full Text] [Related]
19. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors.
Kim DC; Lee YR; Yang BS; Shin KJ; Kim DJ; Chung BY; Yoo KH
Eur J Med Chem; 2003 May; 38(5):525-32. PubMed ID: 12767603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
